7:19 PM
 | 
Jul 25, 2007
 |  BC Extra  |  Company News

Merck to acquire NovaCardia

MRK will acquire NovaCardia (San Diego, Calif.) for $350 million plus the amount of cash on hand at closing, all to be paid in MRK stock. NovaCardia's lead compound is KW-3902, which...

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >